Laura C. Schell

Array ( [id] => 17726624 [patent_doc_number] => 11382989 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-12 [patent_title] => Engineered microbial population [patent_app_type] => utility [patent_app_number] => 16/029686 [patent_app_country] => US [patent_app_date] => 2018-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 37 [patent_no_of_words] => 24192 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16029686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16111699 [patent_doc_number] => 20200207872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => METHODS FOR TREATING INFLAMMATION AND RELATED DISEASES AND DISORDERS BY INHIBITING ALPHA PROTEIN KINASE 1 [patent_app_type] => utility [patent_app_number] => 16/628811 [patent_app_country] => US [patent_app_date] => 2018-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963705 [patent_doc_number] => 20200165604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => LNCRNAS FOR THERAPY AND DIAGNOSIS OF CARDIAC HYPERTROPHY [patent_app_type] => utility [patent_app_number] => 16/017375 [patent_app_country] => US [patent_app_date] => 2018-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19738 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16017375 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16815800 [patent_doc_number] => 11000600 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-05-11 [patent_title] => Exon skipping oligomer conjugates for muscular dystrophy [patent_app_type] => utility [patent_app_number] => 16/001310 [patent_app_country] => US [patent_app_date] => 2018-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 36 [patent_no_of_words] => 33609 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16001310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16013529 [patent_doc_number] => 20200181607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => TETRAMOLECULAR PARALLEL G-QUADRUPLEX-FORMING HYDROPHOBICALLY MODIFIED OLIGONUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 16/617631 [patent_app_country] => US [patent_app_date] => 2018-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16073055 [patent_doc_number] => 20200190514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => NUCLEIC ACID SUPPRESSING EXPRESSION OF APCS [patent_app_type] => utility [patent_app_number] => 16/617743 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14881 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713659 [patent_doc_number] => 11377643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => Therapeutics for glycogen storage disease type III [patent_app_type] => utility [patent_app_number] => 16/617431 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 21120 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16617431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14551675 [patent_doc_number] => 10344282 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-07-09 [patent_title] => Compositions and methods for modulation of IKBKAP splicing [patent_app_type] => utility [patent_app_number] => 15/993090 [patent_app_country] => US [patent_app_date] => 2018-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 17 [patent_no_of_words] => 20414 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15993090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16703059 [patent_doc_number] => 10952972 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-23 [patent_title] => Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same [patent_app_type] => utility [patent_app_number] => 15/988947 [patent_app_country] => US [patent_app_date] => 2018-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 39 [patent_no_of_words] => 24138 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15988947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17235548 [patent_doc_number] => 11179411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Composition for prevention or treatment of spinocerebellar ataxia type 36 [patent_app_type] => utility [patent_app_number] => 16/614644 [patent_app_country] => US [patent_app_date] => 2018-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7699 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16614644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13413773 [patent_doc_number] => 20180258429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-13 [patent_title] => SARNA COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/978670 [patent_app_country] => US [patent_app_date] => 2018-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99112 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 265 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15978670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16206903 [patent_doc_number] => 20200239893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => NEW THERAPY [patent_app_type] => utility [patent_app_number] => 16/612313 [patent_app_country] => US [patent_app_date] => 2018-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12483 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16612313 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15381819 [patent_doc_number] => 10532068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-14 [patent_title] => Dual molecular delivery of oligonucleotides and peptide containing conjugates [patent_app_type] => utility [patent_app_number] => 15/974135 [patent_app_country] => US [patent_app_date] => 2018-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 28540 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15974135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16269148 [patent_doc_number] => 20200270635 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => MODULATORY POLYNUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 16/611046 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 177224 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16611046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16985658 [patent_doc_number] => 11072816 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-27 [patent_title] => Single-cell proteomic assay using aptamers [patent_app_type] => utility [patent_app_number] => 15/970791 [patent_app_country] => US [patent_app_date] => 2018-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 18 [patent_no_of_words] => 29982 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 234 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15970791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13537283 [patent_doc_number] => 20180320188 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-08 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/968520 [patent_app_country] => US [patent_app_date] => 2018-05-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 109644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15968520 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14099089 [patent_doc_number] => 20190091220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-28 [patent_title] => TARGETING PARP1 FOR TREATMENT OF TSC AND CANCERS [patent_app_type] => utility [patent_app_number] => 15/963510 [patent_app_country] => US [patent_app_date] => 2018-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18996 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15963510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15796999 [patent_doc_number] => 20200121642 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-23 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH REDUCED CFTR FUNCTION [patent_app_type] => utility [patent_app_number] => 16/606236 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13131 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13590731 [patent_doc_number] => 20180346914 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => MICRORNA-198 AS A TUMOR SUPPRESSOR IN OVARIAN CANCER [patent_app_type] => utility [patent_app_number] => 15/955451 [patent_app_country] => US [patent_app_date] => 2018-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15955451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357849 [patent_doc_number] => 20180230464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => Chemically Ligated RNAs for CRISPR/Cas9-lgRNA Complexes as Antiviral Therapeutic Agents [patent_app_type] => utility [patent_app_number] => 15/950268 [patent_app_country] => US [patent_app_date] => 2018-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15950268 [rel_patent_id] =>[rel_patent_doc_number] =>)